Charbel Fadel | Pharmacology | Best Researcher Award

Charbel Fadel | Pharmacology | Best Researcher Award

Dr. Charbel Fadel, University of Pisa, Italy

Dr. Charbel Fadel is a renowned researcher in Veterinary Pharmacology with a PhD from the University of Sassari, Italy. He specializes in pharmacotherapy, quality control, and pharmacokinetics. Currently, Dr. Fadel is a Research Fellow at the University of Pisa, Italy, overseeing pharmacology lab operations and conducting animal studies. With a rich background in veterinary medicine, he has contributed to numerous scientific publications and presented at prestigious international conferences. Dr. Fadel’s work is focused on drug disposition, antimicrobial resistance, and improving veterinary pharmacology practices globally. He holds multiple honors and continues to impact veterinary science.

Publication Profile

Scopus

Education

Dr. Charbel Fadel is a distinguished veterinarian with extensive academic qualifications. He earned his Ph.D. in Veterinary Pharmacology, Pharmacotherapy, and Quality Control from the University of Sassari, Italy, in October 2023. Prior to this, he completed a Master’s degree in Veterinary Medicine, specializing in Small Animals’ Medicine, at L’Université Libanaise, Lebanon, in October 2020. His expertise in veterinary pharmacology and small animal care, combined with a passion for enhancing animal health, defines his professional journey.

Experience

Dr. Charbel Fadel has a rich professional background in veterinary medicine. Currently, he serves as a Research Fellow in Veterinary Pharmacology at the University of Pisa, Italy, where he oversees lab operations, manages pharmacokinetic studies, and collaborates with international teams to refine pharmacotherapy strategies. Before this, he was the Project and Operations Manager at IVet Medical in Beirut, Lebanon. In this role, he provided expert guidance to veterinarians on the use of biomedical machines, biological tests, and surgical instruments, while also managing the procurement and evaluation of medical supplies.

Awards

Dr. Charbel Fadel has earned numerous honors throughout his career. He has been an active reviewer for the Journal of Veterinary Pharmacology and Therapeutics since 2023 and was awarded the “Cultore della Materia” honor by the University of Pisa in January 2024 for his work as a Subject Specialist/Adjunct Lecturer. He received second runner-up for the 2023 JVPT Paper Award from Wiley Publishers, and his article on robenacoxib pharmacokinetics was recognized as the most cited in 2022-2023. Dr. Fadel also contributed to the “Rocinate Program” and completed several veterinary training programs in Russia.

Research Focus

Dr. Charbel Fadel’s research focus lies in veterinary pharmacology, particularly in the comparative pharmacokinetics of various drugs in livestock species like sheep and goats. His studies, including those on metronidazole and omeprazole, aim to enhance the understanding of drug absorption, distribution, metabolism, and excretion in these animals. This research is crucial for optimizing veterinary care and ensuring effective medication dosages in different animal species. Dr. Fadel’s work supports the development of more tailored and efficient treatment protocols for livestock, contributing to both animal health and agricultural practices.

Publication Top Notes

Comparative pharmacokinetic evaluation of metronidazole in sheep and goats

Comparative Pharmacokinetics of Intravenous and Subcutaneous Omeprazole in Sheep and Goats

Bekri Melka Abdo | Drug Discovery and Development | Top Pharmaceutical Scientist Award

Bekri Melka Abdo | Drug Discovery and Development | Top Pharmaceutical Scientist Award

Mr. Bekri Melka Abdo, Ethiopian Institute of Agricultural Research, Ethiopia

Bekri Melka Abdo is a dedicated organic chemist specializing in natural product chemistry 🌿. With expertise in plant sample collection, extraction, compound isolation, and structure elucidation, he focuses on bioactive compounds from Ethiopia’s medicinal and aromatic plants. His research contributes to developing natural product-based treatments for leishmaniasis 🦠. He has two published journal articles, an h-index of 7, a Google patent, and an ISBN-registered book 📖. Actively engaged in research and consultancy, Bekri is committed to innovative drug discovery and advancing natural product chemistry for global health.

Publication Profile

orcid

Education

Bekri Melka Abdo is a dedicated professional in organic chemistry 🧪, specializing in natural product chemistry 🌿. His expertise encompasses plant sample collection and preparation, extraction, compound isolation, and structure elucidation. He is skilled in qualitative and quantitative analysis, as well as biological activity determination of natural products extracted from various aromatic and medicinally significant 🌱 exotic and endemic plant species of Ethiopia. With a strong foundation in the field, he contributes to the discovery and characterization of bioactive compounds, supporting advancements in medicine, pharmaceuticals, and biotechnology 🔬. His research plays a vital role in exploring Ethiopia’s rich botanical resources.

Experience 

Bekri Melka Abdo is a passionate researcher in natural product chemistry 🌿, with a strong track record of research and innovation 🔬. He has successfully completed two research projects and maintains an h-index of 7 📊. His contributions extend to industry consultancy and collaborative projects, showcasing his impact in the field. He has authored a book with an ISBN 📖 and has a Google patent pending. His work is recognized in SCI and Scopus-indexed journals 🏅, with two publications. Actively engaged in editorial roles and professional memberships, he continues to drive scientific advancements in bioactive compound discovery.

Award

Bekri Melka Abdo, with his early career achievements and promising research in natural product chemistry 🌿, is an ideal candidate for the Young Scientist Award 🏆. His dedication to bioactive compound discovery, coupled with his impactful contributions to scientific research and innovation 🔬, highlights his potential for future breakthroughs. With a strong foundation in natural product extraction, analysis, and biological activity determination, he is paving the way for new discoveries in medicine and biotechnology 💊. This award category recognizes emerging researchers like Mr. Abdo, whose work demonstrates both excellence and the promise of transformative scientific advancements.

Research Focus

Mr. Bekri Melka Abdo specializes in phytochemistry and antiparasitic drug discovery, focusing on the bioassay-guided isolation of natural compounds for therapeutic applications. His research on dehydrocostus lactone from Echinops kebericho highlights its potential as a leishmanicidal drug 🦟⚕️. His work integrates natural product chemistry, pharmacognosy, and infectious disease research, contributing to novel drug development against leishmaniasis. By combining traditional medicinal plants with modern bioassays, he advances the search for effective, plant-derived antiparasitic treatments 🌱🔬. His research holds promise for addressing neglected tropical diseases through sustainable and nature-inspired therapies.

Hui Xiao | Drug Discovery and Development | Pharmaceutical Innovation Achievement Award

Hui Xiao | Drug Discovery and Development | Pharmaceutical Innovation Achievement Award

Dr Hui Xiao,regeneron,United States

Dr. Hui Xiao 🧪🔬 is a distinguished scientist specializing in biochemistry, structural biology, and mass spectrometry. With a strong focus on microtubule dynamics, protein interactions, and drug mechanisms, he has made significant contributions to understanding cellular processes. As a co-first author and lead researcher, his work has been published in esteemed journals like J. Mol. Biol., Biochemistry, and J. Biol. Chem.. His expertise spans hydrogen-deuterium exchange, proteomics, and molecular stabilization studies. Dr. Xiao’s research has advanced drug discovery, particularly in cancer therapeutics and protein biochemistry. 📚🔍 His innovative approaches continue to impact biomedical sciences globally. 🌍✨

Publication Profile

Scopus

Education

Dr. Hui Xiao 🎓 holds a Ph.D. in Analytical Chemistry from the University of Massachusetts, Amherst (2005) and a degree in Applied Chemistry from Peking University, China (1992). Currently serving as an Associate Director at Regeneron Pharmaceuticals 🏢, he specializes in protein characterization using mass spectrometry. With over a decade at Regeneron, he has progressed through roles as a Senior Staff Scientist and Staff Scientist. Previously, he held academic positions at Albert Einstein College of Medicine 🧬, advancing from Instructor to Research Associate Professor. His expertise spans analytical chemistry, protein analysis, and therapeutic protein research, making significant contributions to biomedical science. 🔬

Professional Impact

Dr. Hui Xiao 🎓 is a distinguished scientist with over 20 years of experience in academia and the biotechnology industry. Currently, he serves as an Associate Director of Analytical Chemistry at Regeneron Pharmaceuticals 🏢, a leading biotech company. His expertise lies in mass spectrometry applications for protein characterization 🔬, contributing to advancements in therapeutic development. Before joining Regeneron, Dr. Xiao held esteemed faculty positions at Albert Einstein College of Medicine 🧬, progressing from Instructor to Research Associate Professor. His extensive research and leadership have played a crucial role in bridging analytical chemistry with biopharmaceutical innovation, impacting drug discovery and development. 🚀

Scientific Contributions

Dr. Hui Xiao 🎓 is a leading expert in protein-ligand interactions, structural proteomics, and therapeutic protein analysis 🔬. His pioneering work includes the application of hydrogen-deuterium exchange mass spectrometry (HDX-MS) for epitope mapping 🧩 and microtubule stabilization research. With a deep focus on drug characterization and regulatory sciences, his contributions have significantly advanced biopharmaceutical development 💊. His expertise in mass spectrometry-driven protein analysis has helped enhance the understanding of molecular mechanisms, improving therapeutic strategies. Through innovation and research, Dr. Xiao continues to play a vital role in shaping the future of biopharmaceutical science and drug discovery. 🚀

Potential Considerations

Dr. Hui Xiao 🎓 is a renowned expert in analytical and protein chemistry, with groundbreaking work in epitope mapping and protein characterization 🔬. While his contributions significantly impact drug development, the Pharmaceutical Innovation Achievement Award 🏆 may prioritize direct advancements in drug discovery and novel pharmaceutical interventions 💊. His research has important regulatory and therapeutic implications, but highlighting specific drug innovations or regulatory breakthroughs he has led would further strengthen his case. By showcasing his role in pioneering pharmaceutical advancements, Dr. Xiao’s influence in shaping modern biopharmaceutical science can be fully recognized and appreciated. 🚀

Research Focus

Dr. Hui Xiao’s research primarily focuses on analytical chemistry 🧪, particularly in the quantitative analysis of biomolecules 🧬 using advanced mass spectrometry techniques ⚖️. His work involves CRISPR sgRNA modification analysis 🧬🔬 and the development of LC-MS-based assays for biological therapeutics 💊. He specializes in phosphorothioate isomer detection 🔄 and liquid chromatography-multiple reaction monitoring-mass spectrometry (LC-MRM-MS) 📊 for precise biomolecular quantification. His contributions are crucial in drug discovery 🏥, gene editing 🧬, and biopharmaceutical development 💉. His expertise bridges biotechnology 🔬 and analytical methodologies 📈, advancing innovations in therapeutic monitoring and molecular diagnostics 🏥.

Publication Top Notes

Quantitative Analysis of Phosphorothioate Isomers in CRISPR sgRNA at Single-Residue Resolution Using Endonuclease Digestion Coupled with Liquid Chromatography Cyclic Ion Mobility Mass Spectrometry (LC/cIMS)

Generic Enrichment Method for Liquid Chromatography-Multiple Reaction Monitoring-Mass Spectrometry Assay for Quantitative Measurement of Biological Therapeutics in Serum

Tang Jin-Bao | Pharmacology | Best Researcher Award

Tang Jin-Bao | Pharmacology | Best Researcher Award

Prof. Dr Tang Jin-Bao,Shandong Second Medical University,China

Prof. Dr. Jin-Bao Tang, a licensed pharmacist in China, is a professor at Shandong Second Medical University. He earned his Ph.D. in Microbial and Biochemical Pharmacy from Shandong University in 2023. An esteemed graduate sponsor in Shandong Province, he specializes in Biotechnological Pharmaceutics and Pharmaceutical Engineering. His research focuses on developing novel immunoassay biosensors for proteins and peptides. With multiple high-impact publications in Food Chemistry and Analytical Bioanalytical Chemistry, he has pioneered advanced immunosensor technologies. His innovative contributions to biosensor development enhance precision in food safety and biomedical analysis. 🔬📚

Publication Profile

Scopus

Education

Prof. Dr. Jin-Bao Tang 🎓 holds a Doctorate in Microbial and Biochemical Pharmacy from Shandong University (2023) and is a licensed pharmacist in China. As a distinguished professor at Shandong Second Medical University, he plays a vital role in educating future pharmaceutical professionals in Biotechnological Pharmaceutics and Pharmaceutics Engineering 🧪. His dedication to academia is evident through his mentorship and contributions to pharmaceutical sciences. Recognized as an excellent graduate sponsor of Shandong Province 🏆, Dr. Tang’s expertise and commitment continue to shape the next generation of researchers and industry leaders in the field of pharmacy. 💊

Scientific Community

Prof. Dr. Jin-Bao Tang 🧑‍🔬 has made a significant impact in the scientific community through his groundbreaking research in biotechnology and pharmacology. His publications appear in prestigious journals such as Food Chemistry, International Journal of Biological Macromolecules, Food Control, and Analytical Bioanalytical Chemistry 📚. His collaborative work has led to advancements in oriented antibody immobilization, photoconjugation strategies, and biosensor technology 🧪, with profound implications for public health, biotechnology, and pharmacological applications. Through his innovative contributions, Prof. Tang continues to shape the future of pharmaceutical sciences, enhancing diagnostic and therapeutic approaches for global healthcare. 🌍💊

Research Contributions

Prof. Dr. Tang Jin-Bao’s research revolves around developing novel immunoassay biosensors for protein and peptide detection 🧪🔬. His pioneering work has significantly advanced biosensing technology, particularly in food safety and biomedical analysis 🍎⚕️. Over the past five years, his high-impact publications have introduced innovative techniques such as electrochemical immunosensors for aflatoxin detection ⚡, bioluminescent immunoassays using antibody-nanoluciferase conjugates ✨, and Fc-specific antibody modifications for enhanced biosensor performance 🧫. Additionally, his photoconjugation strategies have led to stable fluorescent antibody fabrication 🌟. These breakthroughs contribute immensely to food safety, pharmaceutical analysis, and immunodiagnostics, demonstrating the real-world impact of his research. 🚀

Research Focus

Prof. Dr. Jin-Bao Tang’s research primarily focuses on biosensors 🧪, immunoassays 🏥, and antibody engineering 🧬 for food safety and biomedical applications. His work involves developing electrochemical immunosensors ⚡, bioluminescent assays 💡, and advanced antibody modifications 🏗️ to enhance the detection of harmful contaminants like aflatoxin B1 🍄⚠️. He explores oriented antibody immobilization 🎯 to improve sensitivity and specificity in bioanalytical methods. Additionally, his research extends to drug delivery systems 💊, particularly in pulsatile release formulations ⏳, using innovative polymers. His contributions advance food safety 🥗, biomedical diagnostics 🏥, and pharmaceutical technologies 💊 for global health and safety.

Publication Top Notes

A facile and effective electrochemical immunosensor based on controlled and oriented immobilization of natural antibodies for sensitive detection of aflatoxin B1

Development of a bioluminescent immunoassay based on Fc-specific conjugated antibody–nanoluciferase immunoreagents for determining aflatoxin B1

Fabrication of cysteine-modified antibodies with Fc-specific conjugation for covalent and oriented immobilization of native antibodies

Preparation of enteric capsules with pulsatile drug delivery potential using pullulan and polyacrylic acid resin III

Dr. John Thometz|Pharmaceutical Analysis|Excellence in Reach Award

Dr.JohnThometz|Pharmaceutical Analysis|Excellence in Reach Award

Dr. John Thometz at Medical College of WI,United States

PROFILE  

 

Scopus

🏫 Early Academic Pursuits

Dr. John G. Thometz embarked on his academic journey in medical sciences with a strong foundation at Northwestern University, where he earned a Bachelor of Science in Medicine (B.S.M.) in 1973. His commitment to global understanding in medicine took him to Loyola University in Rome, Italy, where he furthered his education in 1974. Dr. Thometz then completed his medical degree (M.D.) at Northwestern Medical School in 1978, after which he was awarded a surgical scholarship at Addenbrooke’s Hospital in Cambridge, England. These experiences laid the groundwork for his illustrious career in orthopedic surgery, with a specialization in pediatric orthopedics.

🩺 Professional Endeavors

Dr. Thometz’s professional career began with intensive training, including a general surgery internship at Loyola University in Chicago, followed by a residency in orthopedic surgery at Northwestern University. His desire to make an impact in pediatric orthopedics led him to Harvard University’s Children’s Hospital, where he completed a fellowship in 1985. Soon after, he joined the Medical College of Wisconsin, where he served as Assistant Professor in the Department of Orthopaedic Surgery. Over the years, his dedication and expertise were recognized with progressive appointments, eventually reaching the rank of Professor in 2000. Dr. Thometz has also held a long-standing role as Adjunct Professor at Marquette University’s Orthopaedic and Rehabilitation Engineering Center (OREC), bridging academic and clinical disciplines.

🔬 Contributions and Research Focus

Dr. Thometz’s research has significantly advanced pediatric orthopedics, with a focus on developing innovative treatments and technologies for children with musculoskeletal disorders. His research spans early-onset scoliosis, cerebral palsy, and spinal deformities. His projects include contributions to critical studies on casting versus bracing in scoliosis treatment, funded by the Orthopaedic Research and Education Foundation (OREF), and a novel study on dynamic pedorthosis for clubfoot correction. In collaboration with the U.S. Department of Health and Human Services and the National Institute on Disability and Rehabilitation Research (NIDILRR), Dr. Thometz has led initiatives to train physicians and engineers in advanced pediatric rehabilitation.

🏅 Accolades and Recognition

Dr. Thometz’s dedication to orthopedic surgery has been widely recognized through numerous accolades, highlighting his commitment to excellence in both teaching and clinical practice. He was named Teacher of the Year twice by the Medical College of Wisconsin’s Department of Orthopaedic Surgery (1988, 2000) and awarded the prestigious Louis A. Goldstein Award for Best Clinical Poster Presentation at the 2010 Scoliosis Research Society Annual Meeting. His expertise has also earned him a consistent place on the Best Doctors in America list, as well as recognition by MKE Lifestyle Magazine for multiple years, underscoring his impact in Milwaukee and beyond.

🌍 Impact and Influence

Beyond his immediate clinical and teaching roles, Dr. Thometz has made substantial contributions to the orthopedic community nationally and internationally. He is an active member and fellow of esteemed organizations, including the American Academy of Orthopaedic Surgeons, the Pediatric Orthopaedic Society of North America, and the Scoliosis Research Society. His work in these societies has focused on advancing pediatric orthopedics and influencing guidelines on nonoperative management strategies, particularly in scoliosis care.

🏛️ Legacy and Future Contributions

As a pioneer in pediatric orthopedic surgery, Dr. Thometz has contributed to foundational research and mentorship that continue to shape the field. His leadership as Medical Director of Pediatric Orthopedic Surgery at the Children’s Hospital of Wisconsin spanned three decades, culminating in his role as Emeritus Medical Director for the Spina Bifida program. Dr. Thometz’s work on advanced rehabilitation technologies and orthopedic interventions continues through his position as Co-Program Director of the Advanced Rehabilitation Research Training (ARRT) in Pediatric Mobility. His legacy is further carried on by his students and residents, many of whom have become leaders in orthopedics. Dr. Thometz’s future contributions are poised to focus on guiding new research, particularly in enhancing pediatric mobility and rehabilitation, with a continued commitment to improving the quality of life for children globally.

🎓Publication 

Analysis of adolescent idiopathic scoliosis population for Surgical Site Infection Risk Factors

  • Authors   :Fletcher, J., Liu, X.-C., Thometz, J.G.
  • Journal    :Journal of Orthopaedics
  • Year         :2025

Correlation of transverse rotation of the spine using surface topography and 3D reconstructive radiography in children with idiopathic scoliosis

  • Authors   : Patel, M., Liu, X.-C., Tassone, C., Yang, K., Thometz, J.
  • Journal    :Spine Deformity
  • Year         :2024

3D Back Contour Metrics in Predicting Idiopathic Scoliosis Progression: Retrospective Cohort Analysis, Case Series Report and Proof of Concept

  • Authors   : Patel, M., Liu, X.-C., Yang, K., Escott, B., Thometz, J.
  • Journal    :Children,
  • Year         :2024

Prophylactic Spinal Cord Untethering in Children with Spinal Dysraphism Undergoing Thoracolumbar Fusion for Scoliosis

  • Authors   :Bureau, B.L., Sherburne, E., Thometz, J.G., Foy, A.B.
  • Journal    :World Neurosurgery
  • Year         :2023

Preoperative left shoulder elevation > 1 cm is predictive of severe postoperative shoulder imbalance in early onset idiopathic scoliosis patients treated with growth-friendly instrumentation

  • Authors   :Li, Y., Yang, D., Bergman, R., Yazici, M., Zhang, T.J.
  • Journal    :Spine Deformity
  • Year         :2023